Neurohumoral activation as a link to systemic manifestations of chronic lung disease

Chest

Volumn 128, Issue 5, 2005, Pages 3618-3624

  Andreas, Stefan ^a   Anker, Stefan D ^b   Scanlon, Paul D ^c   Somers, Virend K ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c MAYO CLINIC   (United States)

Author keywords

Autonomic nervous system; Cachexia; COPD; Muscle

Indexed keywords

NEUROHORMONE;

BREATHING MUSCLE; CACHEXIA; CAUSE OF DEATH; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISABILITY; DISEASE COURSE; HEART FAILURE; HORMONAL REGULATION; HUMAN; INFLAMMATION; LUNG FUNCTION; LUNG VENTILATION; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; SYSTEMIC DISEASE;

EID: 28144464489     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.5.3618     Document Type: Article

References (73)

1. Croxton TL, Weinmann GG, Senior RM, et al. Clinical research in chronic obstructive pulmonary disease: needs and opportunities. Am J Respir Crit Care Med 2003; 167:1142-1149
2. Reid MB. COPD as a muscle disease. Am J Respir Crit Care Med 2001; 164:1101-1102
3. Wouters EF. Chronic obstructive pulmonary disease: 5. Systemic effects of COPD. Thorax 2002; 57:1067-1070
4. Croxton TL, Weinmann GG, Senior RM, et al. Future research directions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165:838-844
5. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333-339
6. Heindl S, Lehnert M, Criée CP, et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001; 164:597-601
7. Volterrani M, Scalvini S, Mazzuero G, et al. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest 1994; 106:1432-1437
8. Scalvini S, Porta R, Zanelli E, et al. Effects of oxygen on autonomic nervous system dysfunction in patients with chronic obstructive pulmonary disease. Eur Respir J 1999; 13:119-124
9. Bartels MN, Gonzalez JM, Kim W, et al. Oxygen supplementation and cardiac-autonomic modulation in COPD. Chest 2000; 118:691-696
10. 1-antitrypsin deficiency. Chest 1998; 113:327-333
11. Stewart AG, Waterhouse JC, Howard P. Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. Eur Respir J 1991; 4:1207-1214
12. Hjalmarsen A, Aasebo U, Aleksandersen G, et al. Cardiovascular responses to tests for autonomic dysfunction in patients with chronic obstructive pulmonary disease with and without continuous long-term oxygen therapy. J Auton Nerv Syst 1996; 60:169-174
13. Watson JP, Nolan J, Elliott MW. Autonomic dysfunction in patients with nocturnal hypoventilation in extrapulmonary restrictive disease. Eur Respir J 1999; 13:1097-1102
14. Kleiger RE, Senior RM. Long-term electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest 1974; 65:483-487
15. Hofford JM, Milakofsky L, Vogel WH, et al. The nutritional status in advanced emphysema associated with chronic bronchitis: a study of amino acid and catecholamine levels. Am Rev Respir Dis 1990; 141:902-908
16. Emerman CL, Cydulka RK. Changes in serum catecholamine levels during acute bronchospasm. Ann Emerg Med 1993; 22:1836-1841
17. Sakamaki F, Satoh T, Nagaya N, et al. Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest 1999; 116:1575-1581
18. Bratel T, Wennlund A, Carlstrom K. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD): effects of long-term oxygen treatment. Respir Med 2000; 94:1221-1228
19. Stewart AG, Waterhouse JC, Billings CG, et al. Effects of angiotensin converting enzyme inhibition on sodium excretion in patients with hypoxaemic chronic obstructive pulmonary disease. Thorax 1994; 49:995-998
20. Kiely DG, Cargill RI, Wheeldon NM, et al. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res 1997; 33:201-208
21. Farber MO, Weinberger MH, Robertson GL, et al. The effects of angiotensin-converting enzyme inhibition on sodium handling in patients with advanced chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 136:862-866
22. Vlahakos DV, Kosmas EN, Dimopoulou I, et al. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 1999; 106:158-164
23. Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med 1995; 89:79-84
24. Chabot F, Mertes PM, Delorme N, et al. Effect of acute hypercapnia on alpha atrial natriuretic peptide, renin, angiotensin II, aldosterone, and vasopressin plasma levels in patients with COPD. Chest 1995; 107:780-786
25. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262:E763-E778
26. Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in preclinical heart failure: remodeling and the potential for intervention. Circulation 1993; 87:IV90-IV96
27. Eckberg DL. Sympathovagal balance: a critical appraisal. Circulation 1997; 96:3224-3232
28. Shields RW Jr. Functional anatomy of the autonomic nervous system. J Clin Neurophysiol 1993; 10:2-13
29. Zhong S, Zhou SY, Gebber GL, et al. Coupled oscillators account for the slow rhythms in sympathetic nerve discharge and phrenic nerve activity. Am J Physiol 1997; 272:R1314-R1324
30. Alvarez GE, Beske SD, Ballard TP, et al. Sympathetic neural activation in visceral obesity. Circulation 2002; 106:2533-2536
31. Hansen J, Sander M. Sympathetic neural overactivity in healthy humans after prolonged exposure to hypobaric hypoxia. J Physiol 2003; 546:921-929
32. Somers VK, Mark AL, Zavala DC, et al. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol 1989; 67:2095-2100
33. Calbet JA. Chronic hypoxia increases blood pressure and noradrenaline spillover in healthy humans. J Physiol 2003; 551:379-386
34. Somers VK, Anderson EA, Mark AL. Sympathetic neural mechanisms in human hypertension. Curr Opin Nephrol Hypertens 1993; 2:96-105
35. Mark AL, Victor RG, Nerhed C, et al. Microneurographic studies of the mechanisms of sympathetic nerve responses to static exercise in humans. Circ Res 1985; 57:461-469
36. Mitchell JH, Schmidt RF. Cardiovascular reflex control by afferent fibers from skeletal muscle receptors. In: Shepherd JT, Abboud FM, eds. Handbook of physiology: the cardiovascular system, 1983
37. Dempsey JA, Sheel AW, St Croix CM, et al. Respiratory influences on sympathetic vasomotor outflow in humans. Respir Physiol Neurobiol 2002; 130:3-20
38. Derchak PA, Sheel AW, Morgan BJ, et al. Effects of expiratory muscle work on muscle sympathetic nerve activity. J Appl Physiol 2002; 92:1539-1552
39. Levine S, Nguyen T, Kaiser LR, et al. Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications. Am J Respir Crit Care Med 2003; 168:706-713
40. Orozco-Levi M, Lloreta J, Minguella J, et al. Injury of the human diaphragm associated with exertion and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1734-1739
41. Seals DR, Suwarno NO, Dempsey JA. Influence of lung volume on sympathetic nerve discharge in normal humans. Circ Res 1990; 67:130-141
42. Goso Y, Asanoi H, Ishise H, et al. Respiratory modulation of muscle sympathetic nerve activity in patients with chronic heart failure. Circulation 2001; 104:418-423
43. Bernardi L, Porta C, Spicuzza L, et al. Slow breathing increases arterial baroreflex sensitivity in patients with chronic heart failure. Circulation 2002; 105:143-145
44. Patakas D, Louridas G, Kakavelas E. Reduced baroreceptor sensitivity in patients with chronic obstructive pulmonary disease. Thorax 1982; 37:292-295
45. Costes F, Roche F, Pichot V, et al. Influence of exercise training on cardiac baroreflex sensitivity in patients with COPD. Eur Respir J 2004; 23:396-401
46. Heistad DD, Wheeler RC, Mark AL, et al. Effects of adrenergic stimulation on ventilation in man. Clin Invest 1956; 51
47. Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure: exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992; 85:2119-2131
48. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999; 115:836-847
49. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248-254
50. Ponikowski P, Piepoli M, Chua TP, et al. The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. Eur Heart J 1999; 20:1667-1675
51. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018
52. Gosker HR, Lencer NH, Franssen FM, et al. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest 2003; 123:1416-1424
53. Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease: clinical relevance and mechanisms. Am J Respir Crit Care Med 2001; 164:1712-1717
54. Mador MJ. Muscle mass, not body weight, predicts outcome in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:787-789
55. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59:574-580
56. Schols AM, Creutzberg EC, Buurman WA, et al. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1220-1226
57. Muers MF, Green JH. Weight loss in chronic obstructive pulmonary disease. Eur Respir J 1993; 6:729-734
58. Woiciechowsky C, Asadullah K, Nestler D, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 1998; 4:808-813
59. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405:458-462
60. Tracey KJ. The inflammatory reflex. Nature 2002; 420:853-859
61. Li M, Zheng C, Sato T, et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004; 109:120-124
62. Snitker S, Tataranni PA, Ravussin E. Respiratory quotient is inversely associated with muscle sympathetic nerve activity. J Clin Endocrinol Metab 1998; 83:3977-3979
63. Takabatake N, Nakamura H, Minamihaba O, et al. A novel pathophysiologic phenomenon in cachexie patients with chronic obstructive pulmonary disease: the relationship between the circadian rhythm of circulating leptin and the very low-frequency component of heart rate variability. Am J Respir Crit Care Med 2001; 163:1314-1319
64. Shamsuzzaman AS, Winnicki M, Wolk R, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109:2181-2185
65. Raguso CA, Guinot SL, Janssens JP, et al. Chronic hypoxia: common traits between chronic obstructive pulmonary disease and altitude. Curr Opin Clin Nutr Metab Care 2004; 7:411-417
66. Duplain H, Vollenweider L, Delabays A, et al. Augmented sympathetic activation during short-term hypoxia and high-altitude exposure in subjects susceptible to high-altitude pulmonary edema. Circulation 1999; 99:1713-1718
67. Dauber IM, Weil JV. Lung injury edema in dogs: influence of sympathetic ablation. J Clin Invest 1983; 72:1977-1986
68. Nishikawa M, Mak JC, Shirasaki H, et al. Long-term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary beta-adrenergic receptors in guinea pigs. Am J Respir Cell Mol Biol 1994; 10:91-99
69. Borst MM, Beuthien W, Schwencke C, et al. Desensitization of the pulmonary adenylyl cyclase system: a cause of airway hyperresponsiveness in congestive heart failure? J Am Coll Cardiol 1999; 34:848-856
70. Weiss ST, Shore S. Obesity and asthma: directions for research. Am J Respir Crit Care Med 2004; 169:963-968
71. Cook DG, Shaper AG. Breathlessness, lung function and the risk of heart attack. Eur Heart J 1988; 9:1215-1222
72. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514-1519
73. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715-725